Published in Clin Res Cardiol on February 24, 2010
Diagnostic accuracy of NT-proBNP ratio (BNP-R) for early diagnosis of tachycardia-mediated cardiomyopathy: a pilot study. Clin Res Cardiol (2011) 0.85
Beta1-adrenoceptor polymorphism predicts flecainide action in patients with atrial fibrillation. PLoS One (2010) 0.80
A novel treatment strategy of new onset atrial fibrillation after cardiac surgery: an observational prospective study. J Cardiothorac Surg (2014) 0.80
A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med (2002) 16.31
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med (1991) 13.91
Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med (2009) 8.51
A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med (2002) 8.37
Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation (2002) 6.20
Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med (2004) 4.19
Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet (2000) 3.36
Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol (2003) 2.73
Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet (2002) 2.49
Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med (1992) 2.07
Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J (2005) 1.71
Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA (1993) 1.60
Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation (2008) 1.51
Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment. Am J Cardiol (1988) 1.21
Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol (2009) 1.08
The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm (2008) 1.03
Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol (1995) 1.02
Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation. Heart (2000) 0.99
Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol (1994) 0.99
Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. Am J Cardiol (1991) 0.96
Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol (2000) 0.94
Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm (2004) 0.93
Efficacy of flecainide for the reversion of acute onset atrial fibrillation. Am J Cardiol (1992) 0.88
Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias. Pharmacotherapy (2009) 0.82
The prognostic impact of successful cardioversion of atrial fibrillation in patients with organic heart disease. Clin Res Cardiol (2006) 0.80
Effects of pretreatment with intravenous flecainide on efficacy of external cardioversion of persistent atrial fibrillation. Pacing Clin Electrophysiol (2004) 0.78
Long-term prognosis after cardioversion of the first episode of symptomatic atrial fibrillation: a condition believed to be benign revised. Clin Res Cardiol (2007) 0.75
The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med (2005) 20.72
Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. N Engl J Med (2015) 8.61
Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation (2013) 3.90
Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol (2012) 3.56
Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J (2006) 3.55
Ischemic preconditioning for prevention of contrast medium-induced nephropathy: randomized pilot RenPro Trial (Renal Protection Trial). Circulation (2012) 3.42
Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J (2005) 2.74
Optimizing engineered heart tissue for therapeutic applications as surrogate heart muscle. Circulation (2006) 2.26
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol (2007) 1.92
Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol (2011) 1.89
Safety and efficacy of exercise training in various forms of pulmonary hypertension. Eur Respir J (2012) 1.83
Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation. Cardiovasc Res (2006) 1.74
Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J (2007) 1.65
Prognostic impact of NT-proBNP and renal function in comparison to contemporary multi-marker risk scores in heart failure patients. Eur J Heart Fail (2008) 1.62
Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Arterioscler Thromb Vasc Biol (2005) 1.61
Microscopic annealing process and its impact on superconductivity in T'-structure electron-doped copper oxides. Nat Mater (2007) 1.56
Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail (2012) 1.53
NT-pro-BNP for differential diagnosis in patients with syncope. Int J Cardiol (2008) 1.49
Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol (2012) 1.48
Postprocedural atrial fibrillation after transcatheter aortic valve implantation versus surgical aortic valve replacement. Ann Thorac Surg (2011) 1.48
Rationale and design of the SERVE-HF study: treatment of sleep-disordered breathing with predominant central sleep apnoea with adaptive servo-ventilation in patients with chronic heart failure. Eur J Heart Fail (2013) 1.47
17Beta-estradiol attenuates PDGF signaling in vascular smooth muscle cells at the postreceptor level. Am J Physiol Heart Circ Physiol (2005) 1.46
In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells. Cell Physiol Biochem (2011) 1.43
QT dispersion in comparison to Tl-201-SPECT for detection of myocardial ischaemia. Int J Cardiol (2006) 1.39
Sarcoplasmic reticulum Ca2+-ATPase modulates cardiac contraction and relaxation. Cardiovasc Res (2003) 1.38
The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care (2004) 1.31
Local versus general anesthesia for transfemoral aortic valve implantation. Clin Res Cardiol (2011) 1.27
Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries. Circ Res (2004) 1.24
Diversity promotes temporal stability across levels of ecosystem organization in experimental grasslands. PLoS One (2010) 1.23
Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. J Am Coll Cardiol (2010) 1.23
Antioxidants relieve phosphatase inhibition and reduce PDGF signaling in cultured VSMCs and in restenosis. Arterioscler Thromb Vasc Biol (2006) 1.21
Phosphatidylinositol 3-kinase-dependent membrane recruitment of Rac-1 and p47phox is critical for alpha-platelet-derived growth factor receptor-induced production of reactive oxygen species. J Biol Chem (2007) 1.19
Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) trial. Eur J Heart Fail (2012) 1.19
Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med (2006) 1.14
Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol (2008) 1.13
A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor. Circ Res (2006) 1.12
Comment on "Clinical trials update from the European Society of Cardiology meeting 2005: CIBIS-III, by JGF Cleland and others". Eur J Heart Fail (2006) 1.10
Effect of exercise and respiratory training on clinical progression and survival in patients with severe chronic pulmonary hypertension. Respiration (2011) 1.10
Imatinib mesylate for the treatment of pulmonary arterial hypertension. Expert Opin Investig Drugs (2011) 1.10
Systematic evaluation of anti-apoptotic growth factor signaling in vascular smooth muscle cells. Only phosphatidylinositol 3'-kinase is important. J Biol Chem (2005) 1.10
C-Peptide induces vascular smooth muscle cell proliferation: involvement of SRC-kinase, phosphatidylinositol 3-kinase, and extracellular signal-regulated kinase 1/2. Circ Res (2006) 1.08
Remote ischemic preconditioning and renoprotection: from myth to a novel therapeutic option? J Am Soc Nephrol (2013) 1.07
Clinical impact of atrial fibrillation in patients with pulmonary hypertension. PLoS One (2012) 1.03
Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J (2008) 1.02
Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis. Diabetes (2008) 1.02
MRI in patients with pacemakers: overview and procedural management. Dtsch Arztebl Int (2012) 1.01
Role of Src tyrosine kinases in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol (2012) 1.01
Matrix-Metallo-Proteinases and their tissue inhibitors in radiation-induced lung injury. Int J Radiat Biol (2007) 1.01
Electronic phase diagram of high-temperature copper oxide superconductors. Proc Natl Acad Sci U S A (2011) 1.00
Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation (2006) 0.99
Testosterone induces cytoprotection by activating ATP-sensitive K+ channels in the cardiac mitochondrial inner membrane. Circulation (2004) 0.97
The Arg389Gly beta1-adrenoceptor gene polymorphism determines contractile response to catecholamines. Pharmacogenetics (2004) 0.97
Chronic thromboembolic pulmonary hypertension (CTEPH): updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol (2011) 0.96
Andersen mutations of KCNJ2 suppress the native inward rectifier current IK1 in a dominant-negative fashion. Cardiovasc Res (2003) 0.96
Mitogen-activated protein kinase modulation of nuclear factor-kappaB-induced granulocyte macrophage-colony-stimulating factor release from human alveolar macrophages. Am J Respir Cell Mol Biol (2003) 0.95
Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Arch Intern Med (2012) 0.95
Elevated MMP-7 levels in patients with systemic sclerosis: correlation with pulmonary involvement. Exp Dermatol (2011) 0.94
Transforming growth factor β₁ oppositely regulates the hypertrophic and contractile response to β-adrenergic stimulation in the heart. PLoS One (2011) 0.94
Hypoxia enhances platelet-derived growth factor signaling in the pulmonary vasculature by down-regulation of protein tyrosine phosphatases. Am J Respir Crit Care Med (2010) 0.93
Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis (2013) 0.93
Local thrombolysis for successful treatment of acute stroke in an adolescent with cardiac myxoma. ScientificWorldJournal (2011) 0.92
The NAD(P)H oxidase inhibitor apocynin improves endothelial NO/superoxide balance and lowers effectively blood pressure in spontaneously hypertensive rats: comparison to calcium channel blockade. Clin Exp Hypertens (2007) 0.91
Predictors of mortality from pump failure and sudden cardiac death in patients with systolic heart failure and left ventricular dyssynchrony: results of the CARE-HF trial. J Card Fail (2008) 0.91
Impact of rescue-thrombolysis during cardiopulmonary resuscitation in patients with pulmonary embolism. PLoS One (2009) 0.90
Profilin-1 is expressed in human atherosclerotic plaques and induces atherogenic effects on vascular smooth muscle cells. PLoS One (2010) 0.89
Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. Eur J Heart Fail (2010) 0.89
A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: an analysis of the PROactive study. Int J Cardiol (2011) 0.89
Effect of cardiac resynchronization on morbidity and mortality of diabetic patients with severe heart failure. Diabetes Care (2007) 0.89
Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin Res Cardiol (2009) 0.89
Protective effects of 10-nitro-oleic acid in a hypoxia-induced murine model of pulmonary hypertension. Am J Respir Cell Mol Biol (2014) 0.88
Influence of dietary state and insulin on myocardial, skeletal muscle and brain [F]-fluorodeoxyglucose kinetics in mice. EJNMMI Res (2011) 0.88
Mortality in a cardiac intensive care unit. Clin Res Cardiol (2012) 0.88
PI3-kinase/Akt-dependent antiapoptotic signaling by the PDGF alpha receptor is negatively regulated by Src family kinases. FEBS Lett (2006) 0.88
Selective inhibition of the pacemaker channel I(f) improves symptoms in severe dilated cardiomyopathy. Clin Res Cardiol (2007) 0.87
K+ channel regulator KCR1 suppresses heart rhythm by modulating the pacemaker current If. PLoS One (2008) 0.87